Management discusses interim clinical data from the Company’s 4D-310 INGLAXA Phase 1/2 clinical trials for treatment of Fabry disease cardiomyopathy and provides an update on clinical development plans on a conference call to be held on February 22 at 4:30 pm. Webcast Link
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
- 4D Molecular to hold a conference call
- 4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
- 4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
- 3 Stocks to Buy Today, 2/7/2023, According to Top Analysts